References
- Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Investigation of fasting ratio of C-peptide/glucose and related markers in diabetes. Archives of Diabetes and Endocrine System 1, 17–24, 2018.10.22259/2638-4981.0101005
- Botros N, Concato J, Mohsenin V, Selim B, Doctor K, Yaggi HK. Obstructive sleep apnea as a risk factor for type 2 diabetes. Am J Med 122, 1122–1127, 2009.10.1016/j.amjmed.2009.04.026279999119958890
- Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110, 2003.10.2337/diabetes.52.1.10212502499
- Chung JO, Park SY, Cho DH, Chung DJ, Chung MY. Anemia, bilirubin, and cardiovascular autonomic neuropathy in patients with type 2 diabetes. Medicine 96, e6586, 2017.10.1097/MD.0000000000006586540308728403090
- Chung JO, Park SY, Cho DH, Chung DJ, Chung MY. Anemia is inversely associated with serum C-peptide concentrations in individuals with type 2 diabetes. Medicine 97, e11783, 2018.10.1097/MD.0000000000011783613339730095635
- Gerber PA, Rutter GA. The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxid Redox Signal 26, 501–518, 2017.2722569010.1089/ars.2016.6755537276727225690
- He BB, Xu M, Wei L, Gu YJ, Han JF, Liu YX, Bao YQ, Jia WP. Relationship between anemia and chronic complications in Chinese patients with type 2 diabetes mellitus. Arch Iran Med 18, 277–283, 2015.25959909
- Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. The relationship between knowledge of recent HbA1c values and diabetes care understanding and self-management. Diabetes Care 28, 816–822, 2005.10.2337/diacare.28.4.81615793179
- Hills CE, Brunskill NJ, Squires PE. C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 31, 389–397, 2010.10.1159/0002898642035743020357430
- Hosseini MS, Rostami Z, Saadat A, Saadatmand SM, Naeimi E. Anemia and microvascular complications in patients with type 2 diabetes mellitus. Nephrourol Mon 6, e19976, 2014.10.5812/numonthly.19976431771525695026
- Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107, 40–45, 1999.10.1055/s-0029-121207110077354
- Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30, 803–817, 2013.10.1111/dme.12159374878823413806
- Kim JD, Kang SJ, Lee MK, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. C-peptide-based index is more related to incident type 2 diabetes in non-diabetic subjects than insulin-based index. Endocrinol Metab 31, 320–327, 2016.10.3803/EnM.2016.31.2.320492341727349701
- Kundu D, Roy A, Mandal T, Bandyopadhyay U, Ghosh E, Ray D. Relation of iron stores to oxidative stress in type 2 diabetes. Niger J Clin Pract 16, 100–103, 2013.10.4103/1119-3077.1067762337748123377481
- Lee EY, Hwang S, Lee SH, Lee YH, Choi AR, Lee Y, Lee BW, Kang ES, Ahn CW, Cha BS, Lee HC. Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes. J Diabetes Investig 5, 517–524, 2014.10.1111/jdi.12187418810925411619
- Luppi P, Kallas A, Wahren J. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes? Diabetes Metab Res Rev 29, 357–362, 2013.10.1002/dmrr.240923463541
- Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66, 1131–1138, 2004.10.1111/j.1523-1755.2004.00863.x1532740815327408
- Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G, Cavallo-Perin P, Bruno G. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32, 301–305, 2009.10.2337/dc08-1241262869719017769
- Ranil PK, Raman R, Rachepalli SR, Pal SS, Kulothungan V, Lakshmipathy P, Satagopan U, Kumaramanickavel G, Sharma T. Anemia and diabetic retinopathy in type 2 diabetes mellitus. J Assoc Physicians India 58, 91–94, 2010.
- Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 25, 275–278, 2002.10.2337/diacare.25.2.27511815495
- Saisho Y, Kou K, Tanaka K, Abe T, Shimada A, Kawai T, Itoh H. Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetol 50, 987–988, 2013.10.1007/s00592-012-0441-y2321266823212668
- Saisho Y. Postprandial C-peptide to glucose ratio as a marker of β cell function: implication for the management of type 2 diabetes. Int J Mol Sci 17, E744, 2016.10.3390/ijms17050744488156627196896
- Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Sjoquist M. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 60, 1258–1265, 2001.1157634010.1046/j.1523-1755.2001.00964.x11576340
- Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 97, 1113–1118, 2005.16173326
- Sato Y, Endo H, Okuyama H, Takeda T, Iwahashi H, Imagawa A, Yamagata K, Shimomura I, Inoue M. Cellular hypoxia of pancreatic β-cells due to high levels of oxygen consumption for insulin secretion in vitro. J Biol Chem 286, 12524–12532, 2011.10.1074/jbc.M110.194738306945421296882
- Sato Y, Inoue M, Yoshizawa T, Yamagata K Moderate hypoxia induces β-cell dysfunction with HIF-1-independent gene expression changes. PLoS One 9, e114868, 2014.10.1371/journal.pone.0114868426476525503986
- Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 23, 339–344, 2000.10.2337/diacare.23.3.33910868862
- The Diabetes Control and Complications Trial Research Group (The DCCT Research Group). The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968–983, 1995.10.2337/diab.44.8.968
- Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 26, 1164–1169, 2003.10.2337/diacare.26.4.116412663591
- Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 3, 20–30, 2007.10.1038/ncpneph037817183259
- Zoppini G, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, Lippi G, Muggeo M, Bonora E. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 210, 575–580, 2010.10.1016/j.atherosclerosis.2009.12.00820031129